Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
JAK2 F547
i
Other names:
JTK10, THCYT3, JAK2, Janus Kinase 2, Tyrosine-Protein Kinase JAK2, JAK-2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3717
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
CRLF2 rearrangement + JAK2 fusion (1)
HMGA1 deletion+ JAK2 V617F (1)
IGH-CRLF2 fusion + JAK2 GPInsR683 (1)
IGH-CRLF2 fusion + JAK2 R867Q (1)
IGH-CRLF2 fusion + JAK2 R683G (1)
JAK2 mutation + MSI-H/dMMR (1)
P2RY8-CRLF2 fusion + JAK2 QGinsR683 (1)
PD-L1 expression + JAK2 mutation (1)
PD-L1 expression + STK11 mutation + JAK2 mutation (1)
RNPC3‐JAK2 fusion + Chr t(1;9)(p13;p22) (1)
HMGA1 deletion+ JAK2 V617 (0)
CRLF2 rearrangement + JAK2 fusion (1)
HMGA1 deletion+ JAK2 V617F (1)
IGH-CRLF2 fusion + JAK2 GPInsR683 (1)
IGH-CRLF2 fusion + JAK2 R867Q (1)
IGH-CRLF2 fusion + JAK2 R683G (1)
JAK2 mutation + MSI-H/dMMR (1)
P2RY8-CRLF2 fusion + JAK2 QGinsR683 (1)
PD-L1 expression + JAK2 mutation (1)
PD-L1 expression + STK11 mutation + JAK2 mutation (1)
RNPC3‐JAK2 fusion + Chr t(1;9)(p13;p22) (1)
HMGA1 deletion+ JAK2 V617 (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
JAK2 F547
Melanoma
JAK2 F547
Melanoma
nivolumab
Resistant: C4 – Case Studies
nivolumab
Resistant
:
C4
nivolumab
Resistant: C4 – Case Studies
nivolumab
Resistant
:
C4
JAK2 F547
Melanoma
JAK2 F547
Melanoma
pembrolizumab
Resistant: C4 – Case Studies
pembrolizumab
Resistant
:
C4
pembrolizumab
Resistant: C4 – Case Studies
pembrolizumab
Resistant
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login